These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 136871)

  • 21. The use of systemic immunity adjuvants in the prophylaxis or therapy of cancer.
    Mathé G; Halle-Pannenko O; Bourut C; Hiu IJ
    Johns Hopkins Med J Suppl; 1974; 3():85-102. PubMed ID: 4154074
    [No Abstract]   [Full Text] [Related]  

  • 22. Mammary tumor growth inhibition in C3H/He mice by long-term Bacillus Calmette-Guérin immunoprophylaxis versus enhancement by primary Bacillus Calmette-Guérin therapy.
    Vaage J
    Cancer Res; 1983 Dec; 43(12 Pt 1):5778-82. PubMed ID: 6357431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.
    Adler A; Altbaum I
    J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interaction of macrophages with tumor cells.
    Stewart CC; Adles C; Hibbs JB
    Adv Exp Med Biol; 1976; 73 Pt B():423-33. PubMed ID: 793342
    [No Abstract]   [Full Text] [Related]  

  • 25. Ultrastructural studies of histiocyte-tumor cell interactions during tumor regression after intralesional injection of Mycobacterium bovis.
    Snodgrass MJ; Hanna MG
    Cancer Res; 1973 Apr; 33(4):701-16. PubMed ID: 4348772
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment of the mouse Lewis tumor by the association of radiotherapy and immunotherapy with Bacillus Calmette-Guérin.
    Dubois JB; Serrou B
    Cancer Res; 1976 May; 36(5):1731-4. PubMed ID: 773530
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic antitumor effects of BCG and monoclonal antibodies capable of inducing antibody-dependent cell-mediated cytotoxicity.
    Komuta K; Kawase I; Ogura T; Masuno T; Yokota S; Hosoe S; Ikeda T; Shirasaka T; Kishimoto S
    Jpn J Cancer Res; 1987 Feb; 78(2):185-92. PubMed ID: 3104261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumor effects of recombinant BCG and interleukin-12 DNA vaccines on xenografted murine bladder cancer.
    Yu DS; Lee CF; Hsieh DS; Chang SY
    Urology; 2004 Mar; 63(3):596-601. PubMed ID: 15028475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Macrophage activation for tumor cytotoxicity: induction of tumoricidal macrophages by supernatants of PPD-stimulated Bacillus Calmette-Guérin-immune spleen cell cultures.
    Ruco LP; Meltzer MS
    J Immunol; 1977 Sep; 119(3):889-96. PubMed ID: 330759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BCG and cancer (first of two parts).
    Bast RC; Zbar B; Borsos T; Rapp HJ
    N Engl J Med; 1974 Jun; 290(25):1413-20. PubMed ID: 4364286
    [No Abstract]   [Full Text] [Related]  

  • 31. Migration of natural suppressor cells from bone marrow to peritoneal cavity by live BCG.
    Kato K; Yamamoto K; Kimura T
    J Immunol; 1985 Dec; 135(6):3661-8. PubMed ID: 2933452
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BCG in cancer immunotherapy: results obtained with various BCG preparations in a screening study for systemic adjuvants applicable to cancer immunoprophylaxis or immunotherapy.
    Mathé G; Halle-Pannenko O; Bourut C
    Natl Cancer Inst Monogr; 1973 Dec; 39():107-13. PubMed ID: 4150738
    [No Abstract]   [Full Text] [Related]  

  • 33. Immunotherapy of murine tumor with syngeneic antitumor serum plus BCG.
    Yamazaki M; Saito M; Abe S; Mizuno D
    Jpn J Exp Med; 1983 Feb; 53(1):27-32. PubMed ID: 6876475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of cell-wall skeleton of Mycobacterium bovis BCG on cell-mediated cytotoxicity in tumor-bearing mice.
    Taniyama T; Azuma I; Aladin AA; Yamamura Y
    Gan; 1975 Dec; 66(6):705-9. PubMed ID: 817955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapeutic studies in mice with the methanol-extraction residue (mer) fraction of BCG: solid tumors.
    Yron I; Weiss DW; Robinson E; Cohen D; Adelberg MG; Mekori T; Haber M
    Natl Cancer Inst Monogr; 1973 Dec; 39():33-55. PubMed ID: 4362523
    [No Abstract]   [Full Text] [Related]  

  • 36. Immunological adjuvants in cancer immunotherapy.
    Baldwin RW
    Dev Biol Stand; 1977 Apr 13-15; 38():3-12. PubMed ID: 344097
    [No Abstract]   [Full Text] [Related]  

  • 37. Radiation therapy and immunotherapy: the value of immunotherapy in the control of local and regional cancer.
    Cancer; 1976 Apr; 37(4 Suppl):2108-19. PubMed ID: 769945
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of M.bovis BCG and M.microti on sarcoma 180 growth in mice.
    Nedvĕdová V; Sír Z; Hyncica V; Buresová M
    Neoplasma; 1978; 25(6):685-90. PubMed ID: 377109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Introduction: animal models of immunotherapy of cancer.
    Rapp HJ
    Natl Cancer Inst Monogr; 1973 Dec; 39():1-2. PubMed ID: 4595318
    [No Abstract]   [Full Text] [Related]  

  • 40. [Effect of sensitization and delayed hypersensitivity reaction on tumor growth in mice].
    Polushkin BV; Gordienko SM
    Vopr Onkol; 1980; 26(7):51-6. PubMed ID: 7405105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.